Posted by Michael Wonder on 01 Mar 2022
CHMP recommends Idorsia’s dual acting treatment Quviviq for insomnia patients
28 February 2022 - Quviviq can be used on a long-term basis, addressing a key limitation of existing therapies
The CHMP has recommended Quviviq (daridorexant) as the first dual orexin receptor antagonist in the EU for the treatment of adult patients with insomnia.
